From the perspective of infection risks caused by encapsulated bacteria, in vitro results with Hib, meningococci and pneumococci indicate potential advantages of AP inhibitors over C3 and C5 inhibitors, in particular, when treatment is combined with prior vaccination of patients (33, 34). The gene discussed is C5; the disease is infection.